ESR1 and cancer: When compared to double-positive cancers, ERα(+)/PgR(−)/HER2(−) tumors displayed higher TP53 and lower PIK3CA mutation rate, and more frequently showed amplification of oncogenes ZNF703 and RPS6KB1 [13,27].